AbbVie Inc.
ABBV
Kedudukan dalam Saham
#25
AbbVie Inc. is a global biopharmaceutical company dedicated to the discovery,... AbbVie Inc. is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and commercialization of advanced medicines. Its extensive therapeutic portfolio encompasses several key areas: Immunology and Inflammation: Leading products include HUMIRA, an injectable therapy for autoimmune and intestinal Behçet's diseases; SKYRIZI, which addresses moderate to severe plaque psoriasis in adults; and RINVOQ, a JAK inhibitor for moderate to severe active rheumatoid arthritis in adult patients. Oncology and Hematology: For blood cancers, AbbVie provides IMBRUVICA and VENCLEXTA (a BCL-2 inhibitor), both indicated for adult patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Virology: MAVYRET offers a treatment option for individuals with chronic HCV genotype 1-6 infection. Gastroenterology and Endocrinology: The company supplies CREON, an enzyme replacement therapy for exocrine pancreatic insufficiency, and Synthroid, used to manage hypothyroidism. Linzess/Constella helps treat irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation. Women's Health and Urology: Lupron serves as a palliative treatment for conditions like advanced prostate cancer, endometriosis, central precocious puberty, and anemia caused by uterine fibroids. ORILISSA, a nonpeptide small molecule GnRH antagonist, is designed for women experiencing moderate to severe endometriosis pain. Neurology: AbbVie offers Duopa and Duodopa, a levodopa-carbidopa intestinal gel for Parkinson's disease, and Ubrelvy to treat migraines (with or without aura) in adults. The therapeutic formulation of Botox is also part of its offerings. Ophthalmology: Its eye care segment features Lumigan/Ganfort (a bimatoprost ophthalmic solution) and Alphagan/Combigan (an alpha-adrenergic receptor agonist), both aimed at reducing elevated intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension. Restasis, a calcineurin inhibitor immunosuppressant, is provided to enhance tear production, alongside other specialized eye care products. AbbVie Inc. also engages in research collaborations, including a partnership with Dragonfly Therapeutics, Inc. The company was founded in 2012 and operates from its headquarters in North Chicago, Illinois.
Harga Saham
$282.96
Modal Pasaran
$500.02B
Perubahan (1 hari)
-0.75%
Perubahan (1 tahun)
23.43%
Negara
US
Perdagangan AbbVie Inc. (ABBV)
Kategori
Healthcare
Nisbah P/B bagi AbbVie Inc. (ABBV)
Nisbah P/B pada February 2026 TTM: -156.00
Menurut laporan kewangan dan harga saham terkini AbbVie Inc., nisbah P/B semasa (TTM) ialah -156.00. Pada akhir 2026, nisbah P/B syarikat ialah 0.
Sejarah nisbah P/B untuk AbbVie Inc. dari 2026 hingga 2026
Nisbah P/B pada akhir setiap tahun
| Tahun | Nisbah P/B | Ubah |
|---|---|---|
| Tidak cukup data untuk tarikh yang disediakan. | ||
Nisbah P/B untuk syarikat atau pesaing yang serupa
| Syarikat | Nisbah P/B | Perbezaan Nisbah P/B | Negara |
|---|---|---|---|
| 31.9092 | -120.45% |
US
|
|
| 7.3138 | -104.69% |
US
|
|
| 8.6873 | -105.57% |
US
|
|
| 8.4776 | -105.43% |
CH
|
|
| 6.754 | -104.33% |
CH
|
